RIGEL (RIGL) Chief Medical Officer receives 18,894-share RSU stock grant

Rhea-AI Filing Summary

Rojkjaer Lisa reported acquisition or exercise transactions in this Form 4 filing.

RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Lisa Rojkjaer received a grant of 18,894 shares of common stock in the form of Restricted Stock Units. These RSUs will vest quarterly over three years, starting with the first vesting on March 31, 2026. After this award, she is reported to beneficially own 34,853 shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rojkjaer Lisa

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	18,894	$0.00	--

Holdings After Transaction: Common Stock — 34,853 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rojkjaer Lisa

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		18,894(1)	A	$0	34,853	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

	/s/ Raymond Furey (Attorney-in-Fact)	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RIGEL (RIGL) report for Lisa Rojkjaer?

RIGEL reported that EVP and Chief Medical Officer Lisa Rojkjaer received a grant of 18,894 Restricted Stock Units. These units represent common stock that will be delivered over time as they vest, aligning her compensation with company performance.

How many RIGEL (RIGL) shares were involved in Lisa Rojkjaer’s award?

The award covers 18,894 shares of RIGEL common stock in the form of Restricted Stock Units. These shares are not issued immediately but will be delivered in installments as the RSUs vest over the three-year schedule.

When do Lisa Rojkjaer’s RIGEL (RIGL) Restricted Stock Units start vesting?

The Restricted Stock Units begin vesting on March 31, 2026. Vesting then continues on a quarterly basis over three years, meaning portions of the 18,894-share award become deliverable at regular three-month intervals after that initial date.

Over what period will the RIGEL (RIGL) RSU grant to Lisa Rojkjaer vest?

The RSU grant will vest quarterly over three years. This structure spreads the delivery of the 18,894 underlying shares across regular vesting dates, supporting long-term retention and linking a significant part of her compensation to continued service.

What is Lisa Rojkjaer’s reported RIGEL (RIGL) share ownership after this award?

Following the reported award, Lisa Rojkjaer is shown as beneficially owning 34,853 shares of RIGEL common stock directly. This total reflects her holdings after including the newly granted equity reported in this insider transaction filing.

Was cash paid for Lisa Rojkjaer’s RIGEL (RIGL) RSU grant?

No cash purchase price is shown for the award, which is reported with a per-share price of 0.0000. This indicates the 18,894 shares were granted as equity compensation rather than bought in an open-market or cash transaction.